Jan Hoffmann

ORCID: 0000-0002-2103-9081
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Migraine and Headache Studies
  • Trigeminal Neuralgia and Treatments
  • Sympathectomy and Hyperhidrosis Treatments
  • Neuroscience of respiration and sleep
  • Cerebral Venous Sinus Thrombosis
  • Ophthalmology and Eye Disorders
  • Olfactory and Sensory Function Studies
  • Neuropeptides and Animal Physiology
  • Pain Mechanisms and Treatments
  • Neurosurgical Procedures and Complications
  • Glaucoma and retinal disorders
  • Intracerebral and Subarachnoid Hemorrhage Research
  • Neurological Disorders and Treatments
  • Neuroscience and Neuropharmacology Research
  • Psychosomatic Disorders and Their Treatments
  • Sleep and Wakefulness Research
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Head and Neck Surgical Oncology
  • German Literature and Culture Studies
  • Biochemical effects in animals
  • Dental Anxiety and Anesthesia Techniques
  • Circadian rhythm and melatonin
  • Pituitary Gland Disorders and Treatments
  • Ocular Diseases and Behçet’s Syndrome
  • Ion Channels and Receptors

King's College London
2017-2025

King's College Hospital
2020-2025

Wellcome Trust
2019-2025

Elmhurst Hospital Center
2025

Northern Michigan University
2024

Johns Hopkins University
2024

University Medical Center Hamburg-Eppendorf
2015-2023

Universität Hamburg
2015-2023

Carnegie Mellon University
2021-2022

Guy's and St Thomas' NHS Foundation Trust
2021

Idiopathic Intracranial Hypertension (IIH) is characterized by an elevation of intracranial pressure (ICP no identifiable cause. The aetiology remains largely unknown, however observations made in a number recent clinical studies are increasing the understanding disease and now provide basis for evidence-based treatment strategies. Embase, CDSR, CENTRAL, DARE MEDLINE databases were searched up to 1st June 2018. We analyzed randomized controlled trials systematic reviews that investigate IIH....

10.1186/s10194-018-0919-2 article EN cc-by The Journal of Headache and Pain 2018-10-08

Objective Pro-inflammatory cytokines like Interleukin-1 beta (IL-1β) have been implicated in the pathophysiology of migraine and inflammatory pain. The trigeminal ganglion calcitonin gene-related peptide (CGRP) are crucial components primary headaches. 5-HT1B/D receptor agonists, which reduce CGRP release, cyclooxygenase (COX) inhibitors can abort trigeminally mediated However, cellular source COX interplay between within not clearly identified. Methods Results 1. We used cultured rat...

10.1371/journal.pone.0017360 article EN cc-by PLoS ONE 2011-03-04

Signaling molecule calcitonin gene-related peptide (CGRP) induces migraine attacks and anti-CGRP medications abort prevent attacks. Whether CGRP provokes cluster headache is unknown.To determine whether in episodic active phase, remission chronic headache.A randomized, double-blind, placebo-controlled, 2-way crossover study set at the Danish Headache Center, Rigshospitalet Glostrup, Denmark. Analyses were intent to treat. Inclusion took place from December 2015 April 2017. criteria diagnosis...

10.1001/jamaneurol.2018.1675 article EN JAMA Neurology 2018-07-09

Objective We aimed at validating established imaging features of idiopathic intracranial hypertension (IIH) by using state-of-the-art MR together with advanced post-processing techniques and correlated findings to clinical scores. Methods Twenty-five IIH patients as well age-, sex- body mass index (BMI)-matched controls underwent high-resolution T1w T2w in a 1.5 T scanner, followed assessment optic nerve sheaths, pituitary gland, ventricles Meckel's cave. Imaging were cerebrospinal fluid...

10.1177/0333102413484095 article EN Cephalalgia 2013-04-24

Introduction Non-invasive vagus nerve stimulation (nVNS; gammaCore®) has the potential to prevent migraine days in patients with on basis of mechanistic rationale and pilot clinical data. Methods This multicentre study included a 4-week run-in period, 12-week double-blind period randomised treatment nVNS or sham, 24-week open-label nVNS. Patients were administer two 120-second stimulations bilaterally neck three times daily (6–8 hours apart). Results Of 477 enrolled patients, 332 comprised...

10.1177/0333102419876920 article EN cc-by-nc Cephalalgia 2019-09-15

10.1007/bf01652397 article DE Journal of Neurology 1893-01-01

The Chordate System administers kinetic oscillation stimulation (K.O.S) into the nasal cavity thereby potentially modulating activity of trigemino-autonomic reflex. Modulation this reflex has been proposed as a potential therapeutic target in migraine. aim clinical trial was to evaluate efficacy K.O.S for preventive treatment chronic migraine (CM). In randomized, double-blind, sham-controlled, multicenter trial, patients with CM were treated once per week over period 6 weeks. primary...

10.1212/wnl.0000000000210220 article EN Neurology 2025-01-09

Objective To evaluate 3D spectral domain optical coherence tomography (SDOCT) volume scans as a tool for quantification of optic nerve head (ONH) potential marker treatment effectiveness and disease progression in idiopathic intracranial hypertension (IIH). Design Patients Cross-sectional pilot trial comparing 19 IIH patients controls matched gender, age body mass index. Each participant underwent SDOCT. A custom segmentation algorithm was developed to quantify ONH (ONHV) height (ONHH)...

10.1371/journal.pone.0036965 article EN cc-by PLoS ONE 2012-05-15

Cranial allodynia associated with spontaneous migraine is reported as either responsive to triptan treatment or be predictive of lack efficacy. These conflicting results suggest that a single mechanism mediating the underlying neurophysiology symptoms unlikely. The translational approach study cranial in patients limitation dissecting potential mechanisms. Our objective was triptan-responsive patients, and develop an studying its neural basis laboratory. Using nitroglycerine trigger attacks,...

10.1093/brain/awy313 article EN cc-by Brain 2018-11-26
Coming Soon ...